...A. The panel will also address the risk-benefit analysis associated with the administration of SRP-9001 for the treatment of ambulatory patients with DMD in the context of accelerated approval, and finally, an assessment of the ability to bring to conclusion EMBARK or Study 301, the proposed post-marketing confirmatory trial to support the accelerated approval of SRP-9001 in the event that accelerated approval is granted. B. First quarter total revenue came in at $253.5 million. C. Net product revenue came in at $231.5 million. D. That's a 23% increase over the same quarter of the prior year and exceeding analyst consensus. E. We continue to progress our important post-marketing commitments for our 3 approved PMO therapies. F. We have already completed 11 of our post-marketing commitments with respect to ESSENCE, which is our 2-year blinded placebo-controlled study for VYONDYS and AMONDYS. G. With respect to MIS51ON, which is our dose-ranging, post-marketing commitment for EXONDYS, Part...
